文献速递乳腺癌

BRCA1/2突变与贝伐珠单抗在三阴性乳腺癌新辅助治疗中的应答与预后:GeparQuinto研究结果

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
PubMed 文献 · J Clin Oncol · 2018-05-23

该研究对GeparQuinto研究中493例三阴性乳腺癌患者进行胚系BRCA1/2测序,分析突变状态与病理完全缓解(pCR)及无病生存(DFS)的关系。结果显示BRCA1/2突变者pCR率显著高于无突变者(50% vs 31.5%),接受贝伐珠单抗者突变携带者pCR率达61.5%。pCR对无突变患者DFS预测强,对突变携带者预测弱。

要点

  • BRCA1/2突变型三阴性乳腺癌患者pCR率显著高于野生型(50% vs 31.5%)。
  • 贝伐珠单抗联合化疗使BRCA1/2突变携带者pCR率提升至61.5%。
  • pCR对BRCA1/2突变携带者DFS的预测价值弱于无突变患者。

核心结论

  • 在含蒽环类和紫杉类的新辅助化疗中加用贝伐珠单抗可能提高BRCA1/2突变型三阴性乳腺癌患者的pCR率。
  • 对于接受含蒽环类和紫杉类方案(±贝伐珠单抗)的患者,pCR对BRCA1/2突变携带者DFS的预测作用弱于无突变患者。

研究设计与样本

  • GeparQuinto研究队列中493例三阴性乳腺癌患者,进行胚系DNA测序鉴定BRCA1/2突变。
  • 比较突变与无突变患者的pCR率,以及接受与未接受贝伐珠单抗患者的pCR率。
  • 评估BRCA1/2突变状态和pCR状态对DFS的影响与治疗的关系。

主要发现

  • 18.3%的三阴性乳腺癌患者检测到BRCA1/2突变。
  • pCR是无突变患者DFS的强预测因子(HR 0.18;95% CI 0.11-0.31),对突变携带者则不显著(HR 0.74;95% CI 0.32-1.69)。

临床怎么用

  • 对三阴性乳腺癌患者可考虑胚系BRCA1/2检测以辅助新辅助治疗决策。
  • BRCA1/2突变携带者可考虑在含蒽环类和紫杉类新辅助化疗基础上加用贝伐珠单抗以提高pCR。
  • 对BRCA1/2突变携带者,pCR不宜作为DFS的强替代终点。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose BRCA1/2 mutations are frequent in patients with triple-negative breast cancer (TNBC). These patients are often treated with primary systemic chemotherapy. The aim of this study was to analyze the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab. Patients and Methods Germline DNA was sequenced to identify mutations in BRCA1 and BRCA2 in 493 patients with TNBC from the GeparQuinto study. The pCR rates were compared in patients with and without mutation, as well as in patients treated with and without bevacizumab. In addition, the influence of BRCA1/2 mutation status and pCR status on DFS was evaluated relative to treatment. Results BRCA1/2 mutations were detected in 18.3% of patients with TNBC. Overall, patients with mutations had a pCR rate of 50%, compared with 31.5% in patients without a mutation (odds ratio [OR], 2.17; 95% CI, 1.37 to 3.46; P = .001). The pCR rate among patients treated with bevacizumab was 61.5% for BRCA1/2 mutation carriers and 35.6% for those without mutations (OR, 2.90; 95% CI, 1.43 to 5.89; P = .004). pCR was a strong predictor of DFS for patients without BRCA1/2 mutations (hazard ratio, 0.18; 95% CI, 0.11 to 0.31) but not for patients with BRCA1/2 mutations (hazard ratio, 0.74; 95% CI, 0.32 to 1.69). Conclusion The addition of bevacizumab may increase the pCR after standard neoadjuvant chemotherapy for patients with TNBC with BRCA1/2 mutations. In patients treated with anthracycline and taxane-based chemotherapy (with or without bevacizumab), pCR was a weaker predictor of DFS for BRCA1/2 mutation carriers than for patients without mutations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fasching PA, Loibl S, Hu C, et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018. PMID: 29791287. doi:10.1200/JCO.2017.77.2285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。